# Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

> **NCT01833754** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 24 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Romosozumab

## Key facts

- **NCT ID:** NCT01833754
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-22
- **Primary completion:** 2014-02-19
- **Final completion:** 2014-02-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833754, "Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01833754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*